Imaging lung function in patients who received stem cell transplants
Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment
M.D. Anderson Cancer Center · NCT05041140
This study is testing a special type of MRI to see how well the lungs are working in adults who have had a stem cell transplant and are having breathing problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05041140 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the use of hyperpolarized 129-Xenon magnetic resonance imaging (129-XeMRI) to assess lung function in adult patients who have undergone allogeneic hematopoietic cell transplantation and are experiencing pulmonary impairment. The study will correlate 129-Xenon imaging results with traditional lung function tests and CT scans to better understand the condition of bronchiolitis obliterans syndrome and its progression. Additionally, it will include a healthy control group for technical calibration of the imaging technology.
Who should consider this trial
Good fit: Ideal candidates include adult patients who have received an allogeneic hematopoietic cell transplant and are experiencing bronchiolitis obliterans syndrome or related pulmonary impairments.
Not a fit: Patients with active pulmonary infections, severe claustrophobia, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method to better diagnose and monitor lung complications in stem cell transplant recipients.
How similar studies have performed: While the use of hyperpolarized gas imaging is a novel approach, similar imaging techniques have shown promise in assessing lung function in other populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Allo-HCT recipients who are at least 18 years of age and have BOS (n=10 patients), BOS 0p (n = 10 patients), or cGVHD of a non-lung organ without evidence of pulmonary impairment (n = 5 patients). Healthy Cohort - Inclusion Criteria: We will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis. Exclusion Criteria: 1. Participants unable to follow up at MD Anderson for routine clinical care 2. Inability or unwillingness to give informed consent 3. Relapsed disease or life expectancy less than 6 months at time of enrollment 4. Severe claustrophobia precluding MRI imaging 5. Active pulmonary infection 6. Pregnant women
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Ajay Sheshadri — M.D. Anderson Cancer Center
- Study coordinator: Ajay Sheshadri
- Email: asheshadri@mdanderson.org
- Phone: (713) 563-1987
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pulmonary, Pneumonia, Hematopoietic System--Cancer